Results 21 to 30 of about 1,576,668 (338)

IL-6 Inhibitors and TNF Inhibitors [PDF]

JACC: Basic to Translational Science
Interleukin-6 inhibitors (IL-6i) are commonly used in patients with rheumatoid arthritis to reduce inflammation from chronically increased IL-6. IL-6 levels increase transiently following exercise, exerting numerous positive effects. This study examined if beneficial exercise-induced cardiac adaptations were attenuated in patients with rheumatoid ...
Simon Jønck, Malte Lund Adamsen, Iben E. Rasmussen, Anna A. Lytzen, Mathilde Løk, Morten Asp Vonsild Lund, Lene Dreyer, Peter G. Jørgensen, Niels Vejlstrup, Lars Køber, Robin Christensen, Søren Jacobsen, Bente Klarlund Pedersen, Helga Ellingsgaard, Pil Højgaard, Ronan M.G. Berg, Regitse Højgaard Christensen   +16 more
openaire   +5 more sources

Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?

Drug Discoveries & Therapeutics, 2020
The world is in the midst of the coronavirus disease 2019 (COVID-19) pandemic. Interleukin 6 (IL-6) inhibitor (tocilizumab) had been suggested for the treatment of acute respiratory distress syndrome (ARDS) patients based on the concept of "cytokine ...
Yuanyuan Zhang, Yanyan Zhong, Lin Pan, J. Dong   +3 more
semanticscholar   +1 more source

Targeting IL-6 trans-signalling: past, present and future prospects

Nature reviews. Immunology, 2023
Interleukin-6 (IL-6) is a key immunomodulatory cytokine that affects the pathogenesis of diverse diseases, including autoimmune diseases, chronic inflammatory conditions and cancer.
S. Rose-John, B. Jenkins, Christoph Garbers, Jens M. Moll, J. Scheller   +4 more
semanticscholar   +1 more source

Effect of IRAK1/4 inhibitor on IL-1β, IL-6, INF-γ and TNF-α expression in breast cancer cells of several lines [PDF]

The Ukrainian Biochemical Journal, 2021
Recent studies have shown that inflammation mediated via interleukin-1 receptor-associated kinases (IRAKs) is associated with cancer cells drug resistance.
M. Rezaei, B. Shahouzehi, S. Rahemi, H. Fallah, M. Salarkarimi   +4 more
doaj   +1 more source

Therapeutic IL-6 trans-signalling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease.

Gastroenterology, 2021
BACKGROUND A large unmet therapeutic need exists in inflammatory bowel diseases (IBD). Inhibition of interleukin (IL)-6 appears to be effective, but the therapeutic benefit of a complete IL-6/IL-6R blockade is limited by profound immunosuppression ...
S. Schreiber, K. Aden, J. P. Bernardes, C. Conrad, F. Tran, H. Höper, Valery Volk, N. Mishra, J. I. Blase, S. Nikolaus, J. Bethge, T. Kühbacher, C. Röcken, Minhu Chen, I. Cottingham, N. Petri, B. B. Rasmussen, J. Lokau, L. Lenk, Christoph Garbers, F. Feuerhake, S. Rose-John, G. H. Waetzig, P. Rosenstiel   +23 more
semanticscholar   +1 more source

Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles

Annals of the Rheumatic Diseases, 2021
Objectives Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe, delayed hypersensitivity reaction (DHR). We observed DRESS to inhibitors of interleukin 1 (IL-1) or IL-6 in a small group of patients with Still’s disease with atypical
V. Saper, M. Ombrello, A. Tremoulet, G. Montero-Martín, S. Prahalad, S. Canna, C. Shimizu, G. Deutsch, Serena Y Tan, E. Remmers, D. Monos, Timothy Hahn, Omkar Phadke, E. Cassidy, I. Ferguson, Vamsee Mallajosyula, Jianpeng Xu, J. S. R. Rosa Duque, G. Chua, Debopam Ghosh, A. Szymanski, D. Rubin, J. Burns, Lu Tian, M. Fernández-Viña, E. Mellins, J. Hollenbach   +26 more
semanticscholar   +1 more source

COMPARATIVE ANALYSIS OF DRUG EFFICACY IN THE TREATMENT FOR COVID-19 SEVERE FORMS, BASED ON ATTRIBUTE-BASED STATISTIC METHODS AND ANALYSIS OF DRUG INTERACTIONS

Фармация и фармакология (Пятигорск), 2021
Severe and critical forms of COVID-19 are beset by the development of “a cytokine storm”, which is characterized by an increased secretion of proinflammatory cytokines.
O. V. Zhukova, I. N. Kagramanyan, A. L. Khokhlov   +2 more
doaj   +1 more source

Interleukin-6 (IL-6) inhibitors as therapeutic agents for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis

Journal of Infection and Public Health, 2021
Introduction Preliminary studies showed that coronavirus disease 2019 (COVID-19) disrupts body immune system, including dysregulation of cytokine interleukin-6 (IL-6).
R. Pinzon, V. Wijaya, Ranbebasa Bijak Buana   +2 more
semanticscholar   +1 more source

Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial

Trials, 2023
Background Administration of Janus kinase (JAK) inhibitors and biological disease-modifying antirheumatic drugs has dramatically improved even the clinical outcomes in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate ...
Toshimasa Shimizu, Shin-ya Kawashiri, Shimpei Morimoto, Yurika Kawazoe, Shohei Kuroda, Rina Kawasaki, Yasuko Ito, Rieko Kiya, Shuntaro Sato, Hiroshi Yamamoto, Atsushi Kawakami   +10 more
doaj   +1 more source

A single aromatic residue in sgp130Fc/olamkicept allows the discrimination between interleukin-6 and interleukin-11 trans-signaling

iScience, 2021
Summary: Blocking the activity of cytokines is an efficient strategy to combat inflammatory diseases. Interleukin-6 (IL-6) fulfills its pro-inflammatory properties via its soluble receptor (IL-6 trans-signaling).
Juliane Lokau, Yvonne Garbers, Joachim Grötzinger, Christoph Garbers   +3 more
doaj   +1 more source